Immunology for
a Better Future

Learn More

Our lead program, Ampligen®, is an immuno-modulator that has shown broad spectrum activity in in-vitro and animal testing and is being evaluated in clinical studies for a range of debilitating and life-threatening conditions.

Learn More

We are working to develop solutions that have the potential to help patients across a number of disease areas, including oncology, immune disorders and viral diseases.

Learn More

Advancing Therapeutic
Solutions

Our lead program, Ampligen®, is an immuno-modulator that has shown broad spectrum activity in in-vitro and animal testing and is being evaluated in clinical studies for a range of debilitating and life-threatening conditions.

Learn More

Focused on Improving
Lives

We are working to develop solutions that have the potential to help patients across a number of disease areas, including oncology, immune disorders and viral diseases.

Learn More

Key Highlights

AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer

Phase 1b portion of the study expected to be completed within six monthsOCALA, Fla., Feb. 14, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced the first subject has been dosed at Erasmus Medical Center ("Erasmus MC") in a Phase...